Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC

被引:0
|
作者
Tan, Jian [1 ]
Ma, Jingbo [1 ]
Zhang, Weiqiang [1 ]
Zhao, Jing [1 ]
Liu, Keqiang [1 ]
机构
[1] Chinese Peoples Liberat Army Gen Hosp, Med Ctr 7, Dept Thorac Surg, 5 Nanmencang, Beijing 100000, Peoples R China
关键词
Forkhead box M1 (FOXM1); MYB-MuvB complex (MMB); Wee1-like protein kinase (WEE1); non-small cell lung cancer (NSCLC); CELL-CYCLE; B-MYB; CANCER; PROLIFERATION; EXPRESSION; KINASE; MUVB;
D O I
10.21037/jtd-23-750
中图分类号
R56 [呼吸系及胸部疾病];
学科分类号
摘要
Background: Non-small cell lung cancer (NSCLC) is a common lung tumor with high mortality. The complex formed by MYB-MuvB complex (MMB) and forkhead box M1 (FOXM1) (MMB-FOXM1) plays a vital role in cell cycle progression to affect the progression of diseases. The role of the FOXM1-MMB complex in Wee1-like protein kinase (WEE1) inhibitor sensitivity in NSCLC keeps unclear. Methods: The reverse transcription quantitative polymerase chain reaction (RT-qPCR) was performed to measure the mRNA levels of FOXM1, LIN54, Replication Protein A (RPA), gammaH2AX (gamma H2AX) and Cyclin B (CCNB). The western blot was performed to examine the corresponding protein expressions. The Cell Counting Kit-8 (CCK-8) assay was performed to test cell survival. Result: It was demonstrated that after AZD-1775 treatment, the decrease in cell survival mediated by FOXM1 overexpression (P<0.001) could be reversed by LIN54 knockdown (P<0.01) and that cell survival in the control group did not differ obviously from that in the pcDNA3.1-FOXM1+siLIN54 group, indicating that the FOXM1-MMB complex was necessary for WEE1 inhibitor sensitivity. Moreover, the mRNA and protein expression levels of RPA and gamma H2AX were increased after AZD-1775 treatment and FOXM1 overexpression (P<0.01), suggesting that FOXM1 upregulation enhanced DNA replication stress and DNA damage. Finally, we found that the increases in the mRNA and protein expression levels of CCNB mediated by FOXM1 (P<0.01) could be rescued by silencing LIN54 (P<0.001) and that CCNB expression in the control group did not differ obviously from that in the pcDNA3.1-FOXM1+siLIN54 group. These findings revealed that the FOXM1-MMB complex activated G2/M checkpoints. In our work, it was discovered that FOXM1 overexpression increased DNA replication stress, which increased DNA replication and pressure on the WEE1 checkpoint. On the other hand, FOXM1 can enhance CCNB expression, increase the threshold content of the CCNB/CDK1 complex, facilitate mitosis, and promote WEE1 dephosphorylation. Under these two conditions, sensitivity to the WEE1 inhibitor AZD-1775 is increased, which leads to the accumulation of DNA damage and drives the activation of apoptosis. Conclusions: Overexpressed FOXM1 collaborates with MMB to increase WEE1 inhibitor sensitivity in NSCLC. This discovery might highlight the regulatory function of FOXM1/MMB in the treatment of NSCLC patients.
引用
收藏
页码:3350 / 3358
页数:9
相关论文
共 50 条
  • [41] Overexpression of PAXIP1 potentiates WEE1 inhibitor action in lung cancer cells
    Jhuraney, Ankita
    Woods, Nicholas T.
    Kinose, Fumi
    Cress, Douglas W.
    Gray, Jhanelle E.
    Haura, Eric B.
    Rix, Uwe
    Monteiro, Alvaro N.
    CANCER RESEARCH, 2014, 74 (19)
  • [42] Novel FOXM1 inhibitor identified via gene network analysis induces autophagic FOXM1 degradation to overcome chemoresistance of human cancer cells
    Chesnokov, Mikhail S.
    Halasi, Marianna
    Borhani, Soheila
    Arbieva, Zarema
    Shah, Binal N.
    Oerlemans, Rick
    Khan, Irum
    Camacho, Carlos J.
    Gartel, Andrei L.
    CELL DEATH & DISEASE, 2021, 12 (07)
  • [43] Sensitization of pancreatic cancer to chemoradiation by the Wee1 inhibitor AZD1775
    Kausar, Tasneem
    Parsels, Leslie A.
    Parsels, Joshua D.
    Karnak, David
    Davis, Mary A.
    Maybaum, Jonathan
    Lawrence, Theodore S.
    Morgan, Meredith A.
    CANCER RESEARCH, 2014, 74 (19)
  • [44] FOXM1 Regulated by ERK Pathway Mediates TGF-β1-Induced EMT in NSCLC
    Kong, Fei-Fei
    Zhu, You-Long
    Yuan, Hai-Hua
    Wang, Jiong-Yi
    Zhao, Mei
    Gong, Xiao-Di
    Liu, Feng
    Zhang, Wen-Ying
    Wang, Cong-Rong
    Jiang, Bin
    ONCOLOGY RESEARCH, 2014, 22 (01) : 29 - 37
  • [45] Evaluation of scheduling for triple therapy gemcitabine/CHEK1 inhibitor/WEE1 inhibitor in pancreatic cancer models
    Koh, Siang-Boon
    Richards, Frances M.
    Wallez, Yann
    Jodrell, Duncan I.
    CANCER RESEARCH, 2016, 76
  • [46] STAT1-mediated inhibition of FOXM1 enhances gemcitabine sensitivity in pancreatic cancer
    Liu, Chao
    Shi, Jiaqi
    Li, Qingwei
    Li, Zhiwei
    Lou, Changjie
    Zhao, Qi
    Zhu, Yuanyuan
    Zhan, Fei
    Lian, Jie
    Wang, Bojun
    Guan, Xin
    Fang, Lin
    Li, Zengxun
    Wang, Yifei
    Zhou, Bodong
    Yao, Yuanfei
    Zhang, Yanqiao
    CLINICAL SCIENCE, 2019, 133 (05) : 645 - 663
  • [47] FOXM1 inhibitor-loaded nanoliposomes for enhanced immunotherapy against cancer
    Shin, Myungsun
    Choi, Young Eun
    Yan, Li
    Goh, Sung-Ho
    Choi, Yongdoo
    CHEMICAL ENGINEERING JOURNAL, 2023, 454
  • [48] Preclinical in vivo evaluation of a novel treatment strategy combining a Wee1 inhibitor with radiotherapy
    Mason, K.
    Pickett, J.
    Ware, C.
    Hirai, H.
    Strack, P.
    Shumway, S. D.
    Ang, K.
    Buchholz, T. A.
    Milas, L.
    Buser, C. A.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [49] Discovery and development of a potent and highly selective WEE1 inhibitor IMP7068
    Cai, Sui Xiong
    Ma, Ning
    Wang, Xiaozhu
    Jiang, Yangzhen
    Zhang, Hongxia
    Guo, Mingchuan
    Zhou, Ruiyu
    Tian, Ye Edward
    CANCER RESEARCH, 2023, 83 (07)
  • [50] Phase II Study of the WEE1 Inhibitor Adavosertib in Recurrent Uterine Serous Carcinoma
    Liu, Joyce F.
    Xiong, Niya
    Campos, Susana M.
    Wright, Alexi A.
    Krasner, Carolyn
    Schumer, Susan
    Horowitz, Neil
    Veneris, Jennifer
    Tayob, Nabihah
    Morrissey, Stephanie
    West, Gabriela
    Quinn, Roxanne
    Matulonis, Ursula A.
    Konstantinopoulos, Panagiotis A.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (14) : 1531 - +